Last reviewed · How we verify

Zofran 8 mg

Medical University of Gdansk · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Zofran 8 mg is a Small molecule drug developed by Medical University of Gdansk. It is currently FDA-approved.

Zofran 8 mg is a small molecule medication used to treat conditions such as dehydration, gastroenteritis, vomiting, diarrhea, and post-operative nausea and vomiting. It is administered as a treatment in emergency departments, particularly for children with gastroenteritis and vomiting.

At a glance

Generic nameZofran 8 mg
SponsorMedical University of Gdansk
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zofran 8 mg

What is Zofran 8 mg?

Zofran 8 mg is a Small molecule drug developed by Medical University of Gdansk.

Who makes Zofran 8 mg?

Zofran 8 mg is developed and marketed by Medical University of Gdansk (see full Medical University of Gdansk pipeline at /company/medical-university-of-gdansk).

What development phase is Zofran 8 mg in?

Zofran 8 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing